---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094896"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-08-12T20:16:29+00:00"
generated_at: "2026-08-12T20:18:37.784136+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Armata posts Q2 net income $74.1M on non-cash gain; AP-SA02 Phase 3 on track

## Summary
- Q2 2026 net income $74.1M vs net loss $16.3M in 2025; basic EPS $2.02, diluted loss $0.27.
- Operating loss $10.3M vs $6.8M; R&D $7.6M, G&A $5.2M; grant revenue $2.5M.
- Received $2.5M additional DoW funding, total $28.7M; cash $24.0M vs $8.7M at end-2025.
- FDA granted Fast Track designation for AP-SA02; Phase 3 protocol submitted; Agreed iPSP obtained.
- Promoted David House to CFO; appointed Daniel B. Gilmer, Ph.D. to board of directors.

## SEC filing metadata
- accession: 0001104659-26-094896
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-08-12T20:16:29+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/0001104659-26-094896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/armp-20260812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094896
- JSON: https://secwatch.observer/filing/0001104659-26-094896.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.